Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Sign \& date informed consent~* Willing \& able to complete trial as described in protocol~* \> 18 years of age~* Meet American College of Rheumatology criteria for Fibromyalgia \[Widespread pain for at least 3 months, including all of the following: (1) Pain on right \& left sides of body; (2) Pain above \& below waist; (3) Pain in axial skeleton; 4) Pain on digital palpation with approximately 4kg force in at least 11 of 18 tender point sites\]~* (Study continuation) Have an average VAS pain score \> 4 on a scale of 0 to 10 as recorded in patient diary the last week before Visit 4.~* Discontinue all prescription medication taken for fibromyalgia, including opiates, benzodiazepines, anticonvulsants taken for pain, antidepressants, cyclobenzaprine (Flexeril), and/or tramadol (Ultram) until study completion~* Continue all pre-existing nutritional and/or exercise regimens and/or behavioral, massage, acupuncture, physical or cognitive therapies on an unchanged, consistent \& regular schedule throughout study~* Use only acetaminophen or over-the-counter non-steroidal anti-inflammatory drugs as rescue pain medications \& to limit dose to the labeled over-the-counter maximum. Aspirin may only be used as a cardiac protectant; formulations with caffeine are excluded.~* Forego ingestion of alcohol for duration of study.~* Fertile females must use a medically accepted method of birth control (e.g., barrier method with spermicide, oral contraceptive, or abstinence) for duration of trial.~Exclusion Criteria~1. Have any of the following medical conditions:~   * Other rheumatic disease, such as rheumatoid arthritis, osteoarthritis, or systemic lupus erythematosis~  * Uncontrolled hypo- or hyper-thyroidism of any type~  * Unstable cardiovascular, endocrine, neoplastic (excluding localized basal cell carcinoma), gastrointestinal, hematologic, hepatic, immunologic, metabolic, neurological, pulmonary, and/or renal disease which would place patient at risk during trial or compromise objectives outlined in protocol~  * Myocardial infarction within last six months~  * On their screening PSG (polysomnogram) have an Apnea Index greater than 10 per hour or an Apnea Hypopnea Index greater than 15 per hour. Note: patients with sleep apnea are not excluded if their indices are below these thresholds while sleeping with CPAP (Continuous Positive Airway Pressure) and they are compliant with CPAP therapy.~  * Problems that, in the investigator's opinion, would preclude the patient's participation and completion of this trial or compromise reliable representation of subjective symptoms.~  * If a patient will have to discontinue antidepressant medication taken for depression, the investigator must make an evaluation as to any risks from cessation of anti-depressant therapy. If, in the opinion of the investigator, a reasonable risk of resultant patient harm exists, patient is excluded from study participation~  * Current or recent history of substance abuse including alcohol abuse~  * History of seizure disorder, history of head trauma, migraine headaches or intracranial surgery, \& are taking anticonvulsants~  * Succinic semialdehyde dehydrogenase deficiency~2. Have taken any of these therapies:~   * gamma-hydroxybutyrate (sodium oxybate) in 30 days prior to signing informed consent~  * any investigational therapy in 30 days prior to signing informed consent~  * ever taken anticonvulsants to treat epilepsy or any other convulsions~3. Unwilling to stop these therapies during course of trial:~   * anticonvulsants prescribed solely for pain~  * all antidepressants~  * medication for sleep~4. Have any of the following clinical laboratory results:~   * Serum creatinine \> 2.0 mg/dL~  * TSH (Thyroid Stimulating Hormone) \< 0.3 μU/mL OR TSH \> 6 μU/mL~  * abnormal liver function tests (SGOT \[AST\] or SGPT \[ALT\] more than twice the upper limit of normal)~  * elevated serum bilirubin (more than 1.5 times the upper limit of normal)~  * pre-trial ECG with arrhythmia, greater than a first degree AV block~  * positive pregnancy test at any time during trial~5. Have any of the following socio-economic factors:~   * Pending worker's compensation litigation or related other monetary settlements~  * Have an occupation that requires variable shift work or routine night shifts

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: EXPERIMENTAL): Sodium oxybate 6.0 g per day.
- 3 (Type: PLACEBO_COMPARATOR): Placebo (one of two doses matching active treatment by volume).
- 1 (Type: EXPERIMENTAL): Sodium oxybate 4.5 g per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).